Immuneering Corporation (IMRX) — Financial statements
Income statement, balance sheet, and cash flow for Immuneering Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.32↓84.8% | 2 | |
| Cost of Revenue | 0.70 | 0.00 | 0.00↓100.0% | 0.16↓86.3% | 1 | |
| Gross Profit | -0.70 | 0.00 | 0.00↓100.0% | 0.16↓82.9% | 0.93 | |
| Operating Expenses | ||||||
| R&D Expenses | 42↓12.3% | 48↑15.2% | 42↑14.8% | 36↑36.6% | 27 | |
| General & Administrative Expenses | 17↑7.6% | 16↓4.1% | 17↑7.4% | 16↑88.7% | 8 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↑7.6% | 16↓4.1% | 17↑7.4% | 16↑88.7% | 8 | |
| Other Expenses | -0.67↓2408.0% | 0.03↑0.5% | 0.03↓2.4% | 0.03 | 0.00 | |
| Operating Expenses | 59↓8.4% | 64↑9.7% | 58↑12.5% | 52↑49.1% | 35 | |
| Total Costs & Expenses | 59↓7.3% | 64↑9.7% | 58↑12.2% | 52↑44.8% | 36 | |
| Operating Results | ||||||
| Operating Income | -59↑7.3% | -64↓9.7% | -58↓12.9% | -52↓52.7% | -34 | |
| Depreciation & Amortization | 0.70↑81.5% | 0.39↑9.4% | 0.35↑27.0% | 0.28↑74.3% | 0.16 | |
| EBITDA | -59↑7.9% | -64↓9.7% | -58↓12.8% | -51↓52.6% | -34 | |
| EBIT | -59↑7.3% | -64↓9.7% | -58↓12.9% | -52↓52.7% | -34 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑17.2% | 3↓28.1% | 4↑255.6% | 1↑497.1% | 0.17 | |
| Interest Income | 3↑17.2% | 3↓28.1% | 4↑255.6% | 1↑497.1% | 0.17 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↓100.0% | 0.00↓36.2% | 0.00↓15.5% | 0.00 | 0.00 | |
| Other Income / Expenses | 3↑10.4% | 3↓38.6% | 5↑301.4% | 1↑2773.5% | 0.04 | |
| Income Before Tax | -56↑8.2% | -61↓14.1% | -53↓5.9% | -51↓49.3% | -34 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.31 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -56↑8.2% | -61↓14.1% | -53↓5.9% | -51↓50.6% | -34 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -56↑8.2% | -61↓14.1% | -53↓5.9% | -51↓50.6% | -34 | |
| Bottom-Line Net Income | -56↑8.2% | -61↓14.1% | -53↓5.9% | -51↓50.6% | -34 | |
| EPS (Basic) | -1.27↑37.7% | -2.04↓8.5% | -1.88↓0.5% | -1.87↓47.2% | -1.27 | |
| EPS (Diluted) | -1.27↑37.7% | -2.04↓8.5% | -1.88↓0.5% | -1.87↓47.2% | -1.27 | |
| Weighted Average Shares | 44↑46.8% | 30↑5.5% | 28↑7.7% | 26↑0.3% | 26 | |
| Weighted Average Diluted Shares | 44↑46.8% | 30↑5.5% | 28↑7.7% | 26↑0.3% | 26 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.